Published in:

01-05-2008 | Original Articles

Safety of regadenoson, a selective adenosine A_2A agonist, in patients with chronic obstructive pulmonary disease: A randomized, double-blind, placebo-controlled trial (RegCOPD trial)

Authors: Gregory S. Thomas, MD, MPH, FACC, FACP, FASNC, Bruce R. Tammelin, MD, FACCP, George L. Schiffman, MD, FACCP, Rudy Marquez, MD, FACCP, Deborah L. Rice, RN, Douglas Milikien, PhD, Vandana Mathur, MD, FASN

Published in: Journal of Nuclear Cardiology | Issue 3/2008